Please login to the form below

Will COVID-19 necessitate a change in thinking around clinical trials?

The global outbreak of coronavirus (COVID-19) and current misinformation infiltrating our consciousness on social media has been a challenge to get our heads around, but it’s undeniable that there’s a public health risk currently proposed by the pandemic. With Italy in lockdown and other countries possibly following suit, will this outbreak impact ongoing clinical studies and those currently enrolling patients?

At the time of writing, it’s unknown how coronavirus spreads from person to person. It’s possible it spreads in cough droplets, like similar viruses. If an individual is advised to self-isolate, whether due to contracting the virus, or coming into contact with someone who has the virus, this will likely have a knock-on effect on clinical studies. People who are currently participating in clinical trials will be unable to attend appointments, and potential participants will be unable to be screened and more hesitant about joining.

The challenge with any clinical study is that every site visit is dictated by the protocol, which has been EC/IRB approved. However, there are options to improve participation that account for the current pandemic:

  • Increase opportunities to part by decentralising: introduce home visits or facilitate assessments through technology platforms
  • Partner with pharmacies and local health settings, who could assist with procedures such as blood tests
  • Post the investigative therapy directly to participants’ homes

These solutions are quick fixes that can ease the burden on healthcare and ensure clinical studies progress without disruption, but any protocol changes will need to be reported for EC/IRB approvals. For instance, the FDA regulations state:

“Each IRB must follow written procedures for ensuring prompt reporting to the IRB of proposed changes in a research activity, and ensuring that changes in approved research, during the period for which IRB approval has already been given, may not be initiated without IRB review and approval except where necessary to eliminate apparent immediate hazards to the human subjects.”

Considering coronavirus is an immediate threat to the safety of people, it is grounds to make the appropriate changes to the study. IRBs should be notified as soon as possible to ensure changes are documented. If you have questions, please contact your local IRB representative and they should be able to help.

The coronavirus has raised some interesting points: why aren’t more studies partially decentralised? Why are pharmacies not able to do blood tests? Why is the investigational drug not shipped to the participant?

The clinical research industry should take learnings from this epidemic, have a period of introspection and work on improving the experience of sites and participants.

This blog was first published here: https://www.couchhealth.co/post/will-covid-19-have-a-short-term-impact-on-clinical-studies

14th March 2020

Share

Tags

Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Address:
Suite 2.10, Jactin House
24 Hood Street
Manchester
M4 6WX
United Kingdom

Latest content on this profile

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need unconscious bias training.”
COUCH Health
How do ethnic minority groups in the U.S. view clinical trials?
This year, we decided to do the same with ethnic minority communities over in the United States (U.S.) too. Ultimately, we wanted to explore attitudes towards clinical trials from these communities, understand the barriers in participation, and determine what factors may influence people’s decisions to take part.
COUCH Health
Three things to consider when using social listening research for patient recruitment
We are looking at how patient research can power your patient recruitment campaign. A look into social listening follows on from this blog perfectly, offering a stronger and more authentic alternative to relying on data trends to guide your activities. So, let’s get started…
COUCH Health
4 ways mobile ethnography studies can elevate your patient insights
How can we achieve more real-life, in-the-moment insights from different groups to understand their thoughts and behaviours? This is where ethnography studies come in.
COUCH Health
#DemandDiversity: We’re calling on the clinical trials industry to include us all
The lack of diversity in clinical trials is something we’ve spoken about time and time again. By now, you might think we sound a bit like a broken record. But, the fact is, many people still aren’t aware of the underrepresentation, especially those who don’t work in the industry. Do you think if the clinical research industry could see the people they were leaving out of clinical trials, and hear how they felt about being underrepresented, it would make a difference?
COUCH Health
Include Us All in Your Clinical Trials

COUCH Health